Stereotaxis Inc (STXS) 1.36 $STXS Stereotaxis Releases

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Stereotaxis Inc (STXS) 1.36 $STXS

Stereotaxis Releases Second Generation V-CAS Deflect(TM) System in Europe
GlobeNewswire - Tue Jul 26, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the market release of its second generation V-CAS Deflect(TM) catheter advancement system in Europe. The V-CAS Deflect catheter advancement system is designed to remotely control a proprietary robotic deflectable sheath during a cardiac ablation procedure with the Stereotaxis Nioberemote magnetic navigation system. The deflectable sheath provides improved support, stability and maneuverability of the magnetic ablation catheter during therapy delivery.
STXS: 1.36 (+0.15)

University of Chicago Medicine Creating High-Tech Arrhythmia Technology Suite with Stereotaxis Niobe(R) ES System
GlobeNewswire - Wed Jul 13, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the University of Chicago Medicine will implement the Company's Niobe ES remote magnetic navigation system as part of its vision to create a cutting-edge arrhythmia technology suite. The University of Chicago Medicine is one of the nation's leading academic medical institutions, consistently ranked among the best hospitals in the nation by U.S. News & World Report. The Center for Arrhythmia Care at the University of Chicago Medicine, led by renowned cardiologist Dr. Roderick Tung, director of the cardiac electrophysiology program, is one of the busiest university-based heart rhythm programs in the Chicago area.
STXS: 1.36 (+0.15)

Stereotaxis to Share its Latest Technology Advancements and Clinical Evidence at Cardiostim 2016 in Nice, France June 8-11
GlobeNewswire - Tue Jun 07, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will share the latest innovations to its Niobe ES magnetic navigation system and supporting clinical evidence at Cardiostim-EHRA Europace 2016, the 20th world congress in cardiac electrophysiology (EP) and cardiac techniques, taking place June 8-11 in Nice, France. The congress brings together more than 5,600 industry practitioners from over 125 countries to discuss the evolution of technologies and research advancements in the treatment of rhythm disorders.
STXS: 1.36 (+0.15)

Paracelsus Medical University Clinical Study on Stereotaxis Technology Benefits Recognized at European Cardiac Arrhythmia Society Congress
GlobeNewswire - Wed Jun 01, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of a retrospective study conducted at Paracelsus Medical University in Nuremberg, Germany, which showed significantly reduced radiation exposure for patients undergoing catheter ablation for persistent atrial fibrillation (AF) with the Niobe magnetic navigation system. The study received first place honors for "Best Poster Presentation" at the European Cardiac Arrhythmia Society Congress in Paris.
STXS: 1.36 (+0.15)

Stereotaxis Reports 2016 First Quarter Financial Results
GlobeNewswire - Mon May 09, 3:05PM CDT
-- Ventricular tachycardia procedures increased 27% year over year, representing the third consecutive quarter of 20%+ volume growth
STXS: 1.36 (+0.15)

Stereotaxis to Highlight New Clinical Results and Automation Enhancements at Heart Rhythm 2016 in San Francisco May 4-7
GlobeNewswire - Wed May 04, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the 37 Annual Heart Rhythm Society (HRS) Scientific Sessions, May 4-7, 2016 in San Francisco. During its 12 consecutive appearance at HRS, the Company will share results of recently published clinical studies, new technology enhancements, user experiences, and simulations of its computer-controlled mapping and lesion formation capabilities at Booth #1631.
STXS: 1.36 (+0.15)

Stereotaxis to Report First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Mon May 02, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2016 first quarter ended March 31, 2016 on Monday, May 9, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
STXS: 1.36 (+0.15)

Stereotaxis Awarded U.S. Patent for Vmotion Spotlight Automation Feature of Vdrive(R) Robotic Navigation System
GlobeNewswire - Fri Apr 29, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,314,222 titled, "Operation of a Remote Medical Navigation System Using Ultrasound Image." The patent protects the current Spotlight feature of the Company's Vmotion suite of automations, which enables automatic orientation of a magnetically compatible Intracardiac Echocardiography (ICE), or ultrasound, catheter to track a localized ablation catheter in conjunction with the Vdrive system with V-Sono ICE catheter manipulator.
STXS: 1.36 (+0.15)

Lund University Hospital Study Validates Improved Long-Term Clinical Outcomes Using Stereotaxis Technology
GlobeNewswire - Thu Apr 07, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of a long-term follow-up study on the efficacy of the Stereotaxis Niobe ES magnetic navigation system reported by Lund University Hospital in Sweden, which validate improved long-term clinical outcomes compared to manual navigation for ablation treatment of atrial fibrillation (AF). The study, presented as a scientific abstract at the American College of Cardiology Scientific Sessions April 2-4, represents the first published long-term clinical outcome results achieved purely with the latest generation Niobe system in AF ablation.
STXS: 1.36 (+0.15)

Change in Short Position and an Important Interview; Stereotaxis, Inc. (NASDAQ: STXS)
ACCESSWIRE - Mon Apr 04, 3:53PM CDT
ST. LOUIS, MO / ACCESSWIRE / April 4, 2016 / Stereotaxis, Inc. (NASDAQ: STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the Hoffman Heart and Vascular Institute at Saint Francis Hospital and Medical Center in Hartford, CT has started getting a lot of attention. We see some interesting information about the short position in this security and a very informative interview all shareholders should see.
STXS: 1.36 (+0.15)

U.S. Hospital Surpasses 1,000 Procedures using Stereotaxis Niobe(R) System
GlobeNewswire - Mon Apr 04, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the Hoffman Heart and Vascular Institute at Saint Francis Hospital and Medical Center in Hartford, CT has completed more than 1,000 cardiac ablation procedures using its Niobe remote magnetic navigation system. Drs. Joseph Dell'Orfano and Aneesh Tolat, electrophysiologists with Arrhythmia Consultants of Connecticut, were among the early adopters of the Niobe system and each has surpassed 500 procedures on the system, making the hospital the leading site in New England to use Stereotaxis technology.
STXS: 1.36 (+0.15)

Centre Hospitalier Regional Universitaire de Nancy Strengthens Leadership in Cardiac Rhythm Management through Stereotaxis Technology
GlobeNewswire - Fri Mar 18, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the first patients treated with the Niobe ES remote magnetic navigation system at the Centre Hospitalier Regional Universitaire de Nancy (CHRU of Nancy) in France. CHRU of Nancy is recognized as a pioneer of electrophysiology (EP) ablations in France, performing more than 900 procedures annually, and represents the fourth institution in the country to implement the Niobe system.
STXS: 1.36 (+0.15)

Journal of Cardiovascular Electrophysiology Publishes Special Issue Dedicated to Stereotaxis Technology
GlobeNewswire - Fri Mar 11, 8:00AM CST
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the Journal of Cardiovascular Electrophysiology (http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1540-8167), a publication of Wiley Periodicals and a leading peer-reviewed journal devoted to the study of electrophysiology (EP) of the heart, has published a special supplemental issue dedicated to Stereotaxis technology. The supplement is the first in the literature to focus solely on the Company's Niobe remote magnetic navigation system and features seven peer-reviewed clinical papers by more than 50 authors studying the results of the Niobe system in catheter ablation of complex arrhythmias.
STXS: 1.36 (+0.15)

University Medical Center New Orleans Implements Stereotaxis Platform for Advanced Treatment of Cardiac Arrhythmias
GlobeNewswire - Mon Feb 01, 8:09AM CST
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, and University Medical Center (UMC) New Orleans, the academic medical center of LCMC Health, today announced the first procedures performed using the Stereotaxis suite of products for electrophysiology (EP) ablation at UMC. The platform includes the Niobe ES remote magnetic navigation system, the Vdriverobotic navigation system and Odyssey information management solutions for lab optimization.
STXS: 1.36 (+0.15)

Stereotaxis Initiates Multi-Center Randomized Superiority Study on Ventricular Tachycardia Ablation Outcomes
GlobeNewswire - Mon Jan 11, 8:00AM CST
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it has initiated its first prospective, multi-center, randomized clinical study to compare radiofrequency ablation outcomes generated using its Niobe ES remote magnetic navigation system to manual approaches in ischemic scar ventricular tachycardia (VT) patients. VT is a rapid heart rhythm that, if left untreated, may lead to ventricular fibrillation and sudden cardiac death. It is estimated that approximately 60,000 ablations are performed annually on a worldwide basis to treat VT, with that number increasing by over 10% each year. In 2015, approximately 2,300 of these 60,000 procedures were performed using the Niobe system.
STXS: 1.36 (+0.15)

Multicenter Study Reveals Improved Long-Term Success Rates With Stereotaxis Technology in Ventricular Tachycardia
GlobeNewswire - Tue Nov 17, 8:00AM CST
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of an independent multicenter study on the procedural benefits and outcomes of patients undergoing radiofrequency ablation therapy for ventricular tachycardia (VT) using the Niobe remote magnetic navigation system compared to manual catheter approaches. The study findings, which were recently published at the American Heart Association Scientific Sessions, represent the most significant long-term outcomes to date with the Niobe system in VT and were considerably better than those in the manual catheter group.
STXS: 1.36 (+0.15)

Stereotaxis Reports 2015 Third Quarter Financial Results
GlobeNewswire - Tue Nov 03, 3:05PM CST
-Total Quarterly Revenue Increased 5% Year over Year on Improved System and Recurring Revenues-
STXS: 1.36 (+0.15)

Stereotaxis to Report Third Quarter 2015 Financial Results on November 3, 2015
GlobeNewswire - Tue Oct 27, 3:07PM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 third quarter ended September 30, 2015 on Tuesday, November 3, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
STXS: 1.36 (+0.15)

Stereotaxis Introduces Respiratory Compensation Feature for Remote Magnetic Navigation Procedures
GlobeNewswire - Mon Oct 12, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the worldwide launch of Respiratory Compensation, a new software feature of the Company's Niobe remote magnetic navigation system. Respiratory Compensation is designed to further enhance the quality and accuracy of Ablation History and the automation features of the Niobe system by compensating for respiratory motion during an ablation procedure.
STXS: 1.36 (+0.15)

Stereotaxis Announces Results of Warrants Offering
GlobeNewswire - Thu Oct 08, 8:00AM CDT
Stereotaxis, Inc. ("Stereotaxis" (NASDAQ:STXS) a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of its previously announced offering of subscription warrants to purchase shares of its common stock at a price of $1.10 per share. Pursuant to the warrants offering, subscription warrants to purchase approximately 0.3 million shares of common stock were exercised, resulting in gross proceeds to Stereotaxis of approximately $300,000.
STXS: 1.36 (+0.15)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 0

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 177

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 52

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 231

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 459

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 23

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 54

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 46

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 373

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 142

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading

Top 5 Most Recently Viewed Articles

Bitcoin’s Price Dynamics: Labor Reports and Elections Impacting Trends

Updated Category News Views 197

Labor Market Reports and Bitcoin's Future Into The Cryptoverse founder Benjamin Cowen shares insights on the current trajectory of Bitcoin as market dynamics shift with upcoming labor market reports and election results. Market Predictions Impacted by External Factors Cowen emphasizes that predictions in the short term remain complex. He notes that the momentum of the...

Continue Reading
Wearable Materials Market Forecast: Growth to USD 9.14 Billion

Updated Category News Views 238

Overview of the Wearable Materials Market The Wearable Materials Market is on an impressive trajectory, with an anticipated growth from USD 3.24 billion in 2024 to USD 9.14 billion by 2032. This surge represents a compounded annual growth rate (CAGR) of 13.85% during the forecast years. Such expansion is astonished by the increasing demand for wearables associated with...

Continue Reading
Strengthening Ties: Xi Jinping and Singaporean PM Wong Unite

Updated Category News Views 382

Strengthening Bilateral Relations for a Brighter Future In a significant meeting that highlights the growing ties between China and Singapore, President Xi Jinping recently welcomed Singaporean Prime Minister Lawrence Wong in Beijing. This engagement underscores the deepening friendship and collaboration between the two nations. During their discussions, President Xi...

Continue Reading
Exploring the Rapid Growth of the Virtual Cards Market

Updated Category News Views 154

Overview of the Virtual Cards Market The global virtual cards market is poised for substantial growth, with estimates suggesting an increase of USD 428.6 billion from 2025 to 2029. A significant annual growth rate of 17.1% during this period is projected, reflecting the ongoing transformations in the payment landscape, particularly driven by advancements in technology and...

Continue Reading
Appian Introduces Advanced AI Features to Revolutionize Workflow

Updated Category News Views 240

Transforming Business Processes with AI Appian, renowned for its innovative process automation solutions, has just rolled out significant enhancements to its platform. By embedding sophisticated AI agents into enterprise workflows, Appian is making strides in automating complex tasks, and empowering business users to revamp outdated applications seamlessly. Empowering...

Continue Reading